RT Journal Article
SR Electronic
T1 Epidemiological characteristics of the B.1.526 SARS-CoV-2 variant
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.08.04.21261596
DO 10.1101/2021.08.04.21261596
A1 Yang, Wan
A1 Greene, Sharon K.
A1 Peterson, Eric R.
A1 Li, Wenhui
A1 Mathes, Robert
A1 Graf, Laura
A1 Lall, Ramona
A1 Hughes, Scott
A1 Wang, Jade
A1 Fine, Anne
YR 2021
UL http://medrxiv.org/content/early/2021/11/23/2021.08.04.21261596.abstract
AB To characterize the epidemiological properties of the B.1.526 SARS-CoV-2 variant of interest, here we utilized nine epidemiological and population datasets and model-inference methods to reconstruct SARS-CoV-2 transmission dynamics in New York City, where B.1.526 emerged. We estimated that B.1.526 had a moderate increase (15-25%) in transmissibility and could escape immunity in 0-10% of previously infected individuals. In addition, B.1.526 substantially increased the infection-fatality risk (IFR) among adults 65 or older by >60% during Nov 2020 – Apr 2021, compared to baseline risk estimated for preexisting variants. Overall, findings suggest that new variants like B.1.526 likely spread in the population weeks prior to detection and that partial immune escape (e.g., resistance to therapeutic antibodies) could offset prior medical advances and increase IFR. Early preparedness for and close monitoring of SARS-CoV-2 variants, their epidemiological characteristics, and disease severity are thus crucial to COVID-19 response as it remains a global public health threat.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by the National Institute of Allergy and Infectious Diseases (AI145883) and the NYC DOHMH.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was classified as public health surveillance and exempt from ethical review and informed consent by the Institutional Review Boards of both Columbia University and NYC DOHMH.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe COVID-19 case and mortality data were used with permission under a Data Use and Nondisclosure Agreement between the New York City Department of Health and Mental Hygiene and Columbia University. The New York City Department of Health and Mental Hygiene also has a comprehensive, publicly available data website here:https://github.com/nychealth/coronavirus-data. Additional data sources are detailed in the manuscript. Model code for the multi-variant, age-structured model and a simpler model-inference system using the ensemble adjustment Kalman filter (EAKF; see ref (32)) is available on Zenodo (ref 39).The COVID-19 case and mortality data were used with permission under a Data Use and Nondisclosure Agreement between the New York City Department of Health and Mental Hygiene and Columbia University. The New York City Department of Health and Mental Hygiene also has a comprehensive, publicly available data website here: https://github.com/nychealth/coronavirus-data. Additional data sources are detailed in the manuscript. Model code for the multi-variant, age-structured model and a simpler model-inference system using the ensemble adjustment Kalman filter (EAKF; see ref (32)) is available on Zenodo (ref 39).